metformin has been researched along with Alopecia in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 8.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Metformin treatment may protect men with early-onset androgenic alopecia against the development of gonadotroph hyperplasia and/or focal testicular changes." | 5.72 | Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 4.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Metformin treatment may protect men with early-onset androgenic alopecia against the development of gonadotroph hyperplasia and/or focal testicular changes." | 1.72 | Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Hair loss or alopecia affects millions worldwide, but methods that can be used to regrow hair are lacking." | 1.51 | Stimulation of Hair Growth by Small Molecules that Activate Autophagy. ( Chai, M; Chu, J; Crooks, GM; de Barros, SC; Doan, NB; Fu, X; Herschman, H; Huang, J; Huang, W; Jiang, M; Jiao, J; Reue, K; Vergnes, L, 2019) |
| "We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®." | 1.46 | Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin. ( Arturi, F; Gallelli, L; Palleria, C; Ruffo, M; Serra, R; Succurro, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Krysiak, R | 2 |
| Kowalcze, K | 2 |
| Okopień, B | 2 |
| Torres-Zegarra, C | 1 |
| Sundararajan, D | 1 |
| Benson, J | 1 |
| Seagle, H | 1 |
| Witten, M | 1 |
| Walders-Abramson, N | 1 |
| Simon, SL | 1 |
| Huguelet, P | 1 |
| Nokoff, NJ | 1 |
| Cree-Green, M | 1 |
| Chai, M | 1 |
| Jiang, M | 1 |
| Vergnes, L | 1 |
| Fu, X | 1 |
| de Barros, SC | 1 |
| Doan, NB | 1 |
| Huang, W | 1 |
| Chu, J | 1 |
| Jiao, J | 1 |
| Herschman, H | 1 |
| Crooks, GM | 1 |
| Reue, K | 1 |
| Huang, J | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Reynolds, RV | 1 |
| Goodman, NF | 1 |
| Cobin, RH | 1 |
| Futterweit, W | 1 |
| Glueck, JS | 1 |
| Legro, RS | 1 |
| Carmina, E | 1 |
| Succurro, E | 1 |
| Palleria, C | 1 |
| Ruffo, M | 1 |
| Serra, R | 1 |
| Arturi, F | 1 |
| Gallelli, L | 1 |
| Langmár, Z | 1 |
| Jothilakshmi, PK | 1 |
| Watson, AJ | 1 |
| Jude, E | 1 |
1 review available for metformin and Alopecia
| Article | Year |
|---|---|
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
8 other studies available for metformin and Alopecia
| Article | Year |
|---|---|
Impaired metabolic effects of metformin in men with early-onset androgenic alopecia.
Topics: Alopecia; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Humans | 2022 |
Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia.
Topics: Adrenocorticotropic Hormone; Alopecia; Androgens; Dehydroepiandrosterone Sulfate; Follicle Stimulati | 2022 |
Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic.
Topics: Adolescent; Adult; Alopecia; Child; Female; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; | 2021 |
Stimulation of Hair Growth by Small Molecules that Activate Autophagy.
Topics: Aging; Allyl Compounds; Alopecia; AMP-Activated Protein Kinases; Animals; Autophagy; Butyrates; Cell | 2019 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine | 2015 |
Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin.
Topics: Aged; Alopecia; Diabetes Mellitus, Type 2; Eyebrows; Eyelashes; Follow-Up Studies; Humans; Hypoglyce | 2017 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe | 2010 |
Acute alopecia due to metformin treatment for polycystic ovarian syndrome.
Topics: Adult; Alopecia; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2006 |